Key result
Finerenone effectively reduced UACR and slowed eGFR decline independently of concomitant SGLT2i use, with early UACR reductions predicting long-term eGFR benefits.
Why the study?
To evaluate the dose-exposure-response effects of finerenone on surrogate markers of kidney failure (UACR and eGFR) in the presence and absence of SGLT2 inhibitors.
Does finerenone improve UACR and eGFR in patients with chronic kidney disease and type 2 diabetes, and is this effect modified by SGLT2 inhibitors?
Does finerenone improve UACR and eGFR in patients with chronic kidney disease and type 2 diabetes, and is this effect modified by SGLT2 inhibitors?
Finerenone reduces UACR and slows eGFR decline independently of concomitant SGLT2 inhibitor use, with early UACR reductions predicting long-term eGFR benefits.
No takes yet. Share an insight, caveat, or question.
Supports concomitant finerenone-SGLT2i use without interaction; leaves open additive outcome benefits in prospective trials.
Goulooze et al. (2022) studied Chronic kidney disease and type 2 diabetes (n=5,674). Finerenone vs. Placebo was evaluated on SGLT2i-finerenone interaction on UACR reduction (95% CI 94.1-122). Finerenone effectively reduced UACR and slowed eGFR decline independently of concomitant SGLT2i use, with early UACR reductions predicting long-term eGFR benefits.